Beyond Paris and New York: The New Powers of the Luxury Skincare Market

Part of the dossier The Nature of Beauty.

When The Estée Lauder Companies announced on 5 March 2026 that it would buy the remaining 51 percent of Forest Essentials, the Indian house grounded in Ayurveda, the group stood in the middle of the deepest restructuring in its history, shedding thousands of staff and running a sale process for Too Faced and Smashbox, its trend-driven colour-cosmetics brands, and for Dr. Jart+, the Korean skincare label it had bought in stages between 2015 and 2019. Its profit had fallen by nearly half across two years, weighed down by the conventional prestige creams that had defined the company for a generation. The one asset it moved to own outright sat in New Delhi, rested on a thousand years of Ayurvedic practice, and lay beyond the reach of any laboratory. Stéphane de La Faverie, chief executive since the start of 2025, was precise about the limits of what his money was buying. The name, the price positioning and the product strategy would stay with the founder, Mira Kulkarni. “Our philosophy is always to honour and respect the brand DNA,” he said. A conglomerate selling the trend brands it had acquired a decade earlier was paying an undisclosed sum to own the one brand whose value it could source only from India.

Three Ways to Make a Luxury Cream, and Three Centres of Power

The purchase forms one sentence of a much longer argument, and the argument concerns where luxury skincare is now made. For most of a century the answer sat in Paris, with New York amplifying it, and the rest of the world supplying either the raw plant or the paying customer. That arrangement has come apart within a few years, and the Forest Essentials deal stands as the clearest evidence yet that the largest Western houses see the change and now pay to catch up to it. The luxury tier of skincare, the segment above 100 dollars a jar where the market analysts draw their line, has organised itself into three ways of making a cream, and each of the three gives its advantage to a different part of the world.

The line where luxury begins is a specific number, 100 dollars for a standard jar in 2026, the point the analysts at Precedence Research and Future Market Insights use to separate prestige from true luxury. What changes at that number is physical as much as commercial. Below it the formula leads with distilled water and the brand makes the sale; above it the water gives way to a plant hydrolat or a fermented broth, the active molecules run three to five times denser, and the packaging turns to weighted opal glass. The pure high-end above the line reaches close to 30 billion dollars in 2026, and the wider premium field that includes dermatological and pharmacy skincare comes to around 129 billion, with more than 40 percent of demand now originating in Asia. Price marks the entry to the story here in the way the six-figure line marks where collectible watchmaking begins, a threshold rather than the subject itself.

Raw and Wildcrafted Botanicals: The Margin in the Untouched Plant

The first way of making a luxury cream keeps the plant intact, and it belongs to the global South by inheritance. In the segment the market calls Raw & Wildcrafted Botanicals, sold under the term Provenance Beauty, the raw material reaches the jar chemically unchanged, pressed or distilled by mechanical means, suspended in its own sap. The economics are unlike anything else in the market. Research runs at 2 to 3 percent of revenue, the lowest of the three segments, because there is neither a fermentation programme nor a clinical trial to fund; gross margin reaches 82 percent, the highest of the three, because the price answers to the scarcity of the origin rather than to the cost of production. Wild Hojari frankincense from the Dhofar coast of Oman and hand-processed shea from the Sahel keep their value because their supply is finite and the traceable line back to the harvest is the product itself.

India is the centre of this segment, and the two largest Western beauty groups have each responded to that fact the same way, by acquisition. Estée Lauder is buying Forest Essentials; Puig, the Spanish family group, took majority control of Kama Ayurveda in 2022, four years after its first minority investment in 2019, and owns the Colombian house Loto del Sur alongside it. Two rivals reaching independently for the same Indian shelf is the whole diagnosis in miniature: the cultural authority of Ayurveda has become a strategic asset, and it is one a Paris or New York headquarters can purchase but not originate. India’s premium Ayurvedic market alone runs at 4 to 5 billion dollars and grows 15 to 18 percent a year, faster than any premium tier in the West. The same logic recurs across the map, in the A-Beauty houses like South Africa’s Africology, which reaches the world’s ultra-luxury spas and safari lodges with marula and rooibos through the resort rather than the counter, and in Europe’s own answer, Furtuna Skin, which took an 800-hectare Sicilian estate into private ownership because owning the ground is the one way a Western brand can manufacture the provenance the global South possesses by inheritance.

Green Biotech and Biosynthetics: The Science Korea and Japan Command

The second way of making a luxury cream rebuilds the plant, and it is the field where the shift is most expensive to reverse, because it rests on decades of research already spent. In the segment sold as Skin Longevity, a single plant cell is isolated and multiplied by fermentation until it yields a molecule more concentrated than the wild plant ever produced. The cost structure is the mirror image of provenance: research consumes 7 to 12 percent of revenue, capital is committed for the 5 to 7 years a stable process takes to mature, and the patent that follows secures pricing power for its full term. It is the fastest-growing field in all of beauty, close to 50 billion dollars in 2026, expanding above 9 percent a year and past 10 percent in China, and forecast to more than double within the decade. The growth that the opening article of this dossier, Beauty Outgrows the Core, traced across the whole industry is generated, more than anywhere, in these laboratories.

The advantage was built in Korea and Japan, and it divides into three distinct methods. The first is bio-fermentation, the conversion of an existing plant into a compound it never contained: Amorepacific transforms ordinary ginseng enzymatically into its patented Ginsenomics complex, a few grams from a tonne of root, and LG Household & Health Care ferments more than 80 seasonal plants for a full year at a constant 37 degrees for the elixir behind Su:m37, while in Japan Shiseido stabilises a longevity molecule from a mountain herb for its Future Solution LX line and Kosé, the fermentation pioneer, prices its Decorté AQ Meliority above 1,000 dollars a jar. The second method is precision fermentation, which programmes living micro-organisms to build a molecule from nothing, vegan collagen among them, and it belongs to Latin America through Brazil’s Natura, whose Chronos line submits Amazonian botanicals to clinical trials at a medical standard and, in the same act, satisfies the vegan and halal requirements that govern the Gulf. The third method is epigenetic peptide synthesis, the assembly of a signalling molecule that instructs the skin’s own cells, and it is Europe’s single native position, the ground of Augustinus Bader. Where the West owns a place in this segment it has often bought one, as Coty did with Orveda, a house of pure fermentation built on cultured yeast and marine enzymes.